Advancements and Challenges in Islet Transplantation for Type 1 Diabetes: A Comprehensive Review of Techniques, Long-Term Outcomes, and Emerging Strategies

Abstract

Islet transplantation has emerged as a promising therapeutic approach for individuals with type 1 diabetes (T1D) aiming to restore glycemic control and reduce reliance on exogenous insulin. While the Edmonton Protocol marked a significant milestone in this field, long-term insulin independence remains a challenge due to factors such as immune rejection, islet graft failure, and the inherent limitations of current transplantation techniques. This research report delves into the intricacies of islet transplantation, exploring the various methodologies employed, the persistent hurdles encountered, and the innovative strategies being developed to enhance graft survival and functionality. We critically evaluate the evolving landscape of islet transplantation, comparing different transplantation sites, immunosuppression regimens, and pre- and post-transplant care protocols. Furthermore, we examine the ethical considerations surrounding islet procurement and allocation, and contrast islet transplantation with other emerging therapies, including stem cell-derived beta cells and artificial pancreas systems. This report aims to provide a comprehensive overview for experts in the field, highlighting recent advances and future directions in islet transplantation research.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Type 1 diabetes (T1D) is an autoimmune disease characterized by the selective destruction of insulin-producing beta cells in the pancreatic islets of Langerhans. The resulting insulin deficiency leads to hyperglycemia and necessitates lifelong insulin therapy to maintain metabolic control. While exogenous insulin administration can prevent acute complications such as diabetic ketoacidosis, achieving tight glycemic control remains challenging, and patients are still at risk for long-term complications, including retinopathy, nephropathy, neuropathy, and cardiovascular disease [1].

Islet transplantation offers a potential cure for T1D by replacing the destroyed beta cells with healthy, functional islets from deceased donors. The goal of islet transplantation is to restore endogenous insulin production, thereby eliminating the need for exogenous insulin and improving glycemic control. The procedure involves isolating islets from a donor pancreas and infusing them into the recipient’s liver, typically via the portal vein. The transplanted islets then engraft in the liver and begin to produce insulin in response to changes in blood glucose levels [2].

The Edmonton Protocol, introduced in 2000, represented a major advancement in islet transplantation, demonstrating the ability to achieve insulin independence in a significant proportion of patients. The protocol involved the use of a steroid-free immunosuppression regimen consisting of sirolimus and tacrolimus, which reduced the toxicity associated with traditional immunosuppressants. However, long-term insulin independence rates remained suboptimal, highlighting the need for further improvements in transplantation techniques and immunosuppression strategies [3].

This report aims to provide a comprehensive review of islet transplantation for T1D, encompassing the various aspects of the procedure, the challenges faced, and the emerging strategies being developed to improve outcomes. We will discuss the different transplantation sites being explored, the advances in immunosuppression regimens, the strategies to improve islet survival and function, the ethical considerations surrounding islet transplantation, and the comparison of islet transplantation with other emerging therapies for T1D.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Islet Isolation and Preparation

The success of islet transplantation heavily relies on the quality and quantity of islets isolated from the donor pancreas. The islet isolation process involves a series of enzymatic digestion and purification steps to separate the islets from the surrounding exocrine tissue [4].

The most commonly used enzyme for islet isolation is collagenase, which is infused into the pancreatic duct to digest the extracellular matrix surrounding the islets. The digested pancreas is then processed through a density gradient centrifugation to separate the islets from the exocrine tissue. The purified islets are then assessed for viability, purity, and insulin content before being transplanted into the recipient [5].

The islet isolation process is technically challenging and requires specialized equipment and expertise. The yield and quality of islets obtained can vary significantly depending on factors such as donor age, pancreatic preservation time, and the isolation technique used. Several modifications have been made to the islet isolation process to improve islet yield and viability, including the use of automated isolation systems, optimized enzyme formulations, and improved preservation techniques [6].

Pre-transplant islet culture is also increasingly being employed to improve islet function and reduce immunogenicity. This involves culturing the isolated islets in specialized media for several days before transplantation, which allows for the removal of damaged cells and the enhancement of islet function. Furthermore, genetic modification of islets before transplantation is being investigated as a means to improve their survival and function in the recipient [7].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Transplantation Sites and Techniques

The liver is the most common site for islet transplantation due to its accessibility and vascularity. The islets are typically infused into the portal vein, which carries blood from the intestines to the liver. The transplanted islets then engraft in the liver sinusoids and begin to produce insulin [8].

However, the liver is not an ideal transplantation site due to several limitations, including the instant blood-mediated inflammatory reaction (IBMIR), which can damage the transplanted islets, and the exposure of the islets to high concentrations of immunosuppressants [9]. The liver also lacks the optimal microenvironment for islet survival and function, leading to progressive loss of graft function over time.

Alternative transplantation sites are being explored to overcome the limitations of the liver, including the subcutaneous space, the omentum, and the kidney capsule. The subcutaneous space offers several advantages, including ease of access and the ability to monitor graft function non-invasively. However, the subcutaneous space lacks the vascularity necessary to support islet survival, and the transplanted islets can be susceptible to fibrosis and encapsulation [10].

The omentum is a highly vascularized tissue located in the abdominal cavity that offers a promising alternative transplantation site. The omentum provides a rich blood supply and a favorable microenvironment for islet survival and function. However, transplantation into the omentum requires a more invasive surgical procedure compared to liver transplantation [11].

The kidney capsule is another alternative transplantation site that offers a rich blood supply and immune-privileged environment. However, transplantation into the kidney capsule is technically challenging and can potentially damage the kidney [12].

Ultimately, the ideal transplantation site remains a subject of ongoing research. Future studies will need to compare the long-term outcomes of islet transplantation at different sites to determine the optimal location for islet engraftment and function.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Immunosuppression Strategies

Immunosuppression is a critical component of islet transplantation to prevent rejection of the transplanted islets by the recipient’s immune system. The Edmonton Protocol, which involves the use of sirolimus and tacrolimus, has been widely adopted as the standard immunosuppression regimen for islet transplantation [3].

However, sirolimus and tacrolimus are associated with several side effects, including nephrotoxicity, hypertension, and hyperlipidemia. These side effects can limit the long-term use of these drugs and contribute to graft failure. Therefore, there is a need for alternative immunosuppression strategies that are less toxic and more effective at preventing rejection [13].

Several novel immunosuppressants are being investigated for use in islet transplantation, including belatacept, a CTLA-4 immunoglobulin fusion protein that blocks T cell activation, and alemtuzumab, a monoclonal antibody that depletes T cells. These drugs have shown promise in preventing rejection and improving graft survival in clinical trials [14, 15].

Tolerogenic strategies are also being developed to induce immune tolerance to the transplanted islets, thereby eliminating the need for chronic immunosuppression. These strategies involve the use of agents that promote the development of regulatory T cells, which suppress the immune response to the transplanted islets [16].

Encapsulation of islets in biocompatible materials is another approach to protect the transplanted islets from immune rejection. Encapsulation involves enclosing the islets in a semi-permeable membrane that allows the passage of nutrients and insulin but prevents the entry of immune cells. Encapsulation can potentially eliminate the need for immunosuppression, but the long-term biocompatibility and functionality of encapsulated islets remain a challenge [17].

Ultimately, the ideal immunosuppression strategy will be one that effectively prevents rejection without causing significant side effects and ideally inducing long-term tolerance to the graft. Future research will need to focus on developing and testing novel immunosuppressants and tolerogenic strategies to improve the outcomes of islet transplantation.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Long-Term Outcomes and Challenges

While islet transplantation can achieve insulin independence in a significant proportion of patients, long-term insulin independence rates remain suboptimal. Several factors contribute to the loss of graft function over time, including immune rejection, islet graft failure, and the recurrence of autoimmunity [18].

Chronic rejection is a major cause of graft failure in islet transplantation. Chronic rejection is characterized by the gradual destruction of the transplanted islets by the recipient’s immune system, despite the use of immunosuppressants. Strategies to prevent chronic rejection include the use of more effective immunosuppressants, the induction of immune tolerance, and the protection of islets from immune attack through encapsulation or genetic modification [19].

Islet graft failure can also occur due to non-immune-mediated factors, such as islet hypoxia, inflammation, and apoptosis. The liver, being the most common transplantation site, is not the most ideal environment for long-term islet survival due to the instant blood-mediated inflammatory reaction (IBMIR) and other factors [9]. Strategies to improve islet survival include the optimization of transplantation techniques, the use of anti-apoptotic agents, and the development of more biocompatible transplantation sites [20].

The recurrence of autoimmunity can also contribute to graft failure in islet transplantation. Autoimmunity is the process by which the recipient’s immune system attacks its own tissues, including the transplanted islets. Strategies to prevent the recurrence of autoimmunity include the use of immunosuppressants that target autoimmune T cells and the development of therapies that promote immune tolerance [21].

Furthermore, the progressive decline in beta-cell function after islet transplantation can contribute to the loss of insulin independence. This decline can be attributed to several factors, including the limited replicative capacity of transplanted islets, the effects of immunosuppressants on beta-cell function, and the development of insulin resistance. Strategies to maintain beta-cell function include the use of agents that promote beta-cell proliferation, the optimization of immunosuppression regimens, and the improvement of insulin sensitivity [22].

Addressing these challenges is critical to improving the long-term outcomes of islet transplantation and achieving a durable cure for T1D.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Ethical Considerations

Islet transplantation raises several ethical considerations related to islet procurement, allocation, and the risks and benefits of the procedure. Islets are typically obtained from deceased donors, raising concerns about the fairness and transparency of the organ donation process [23].

The allocation of scarce islet resources is another ethical challenge. Islets are in high demand, and there are not enough islets available to meet the needs of all patients with T1D. Therefore, it is necessary to develop fair and transparent criteria for allocating islets to recipients [24].

The risks and benefits of islet transplantation must also be carefully considered. Islet transplantation is an invasive procedure that requires lifelong immunosuppression, which can have significant side effects. Patients must be fully informed about the risks and benefits of the procedure before making a decision about whether to undergo transplantation [25].

Furthermore, the use of experimental therapies, such as encapsulated islets and genetically modified islets, raises additional ethical concerns. These therapies are not yet fully proven, and their long-term safety and efficacy are uncertain. Patients must be fully informed about the experimental nature of these therapies before participating in clinical trials [26].

Open and transparent discussions about these ethical considerations are essential to ensure that islet transplantation is conducted in a responsible and ethical manner.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Comparison with Emerging Therapies

Islet transplantation is not the only emerging therapy for T1D. Other promising approaches include stem cell-derived beta cells and artificial pancreas systems. Each of these therapies has its own advantages and disadvantages, and the optimal treatment strategy for T1D may vary depending on the individual patient [27].

Stem cell-derived beta cells offer the potential to generate an unlimited supply of functional beta cells for transplantation. Several research groups have developed protocols for differentiating human embryonic stem cells and induced pluripotent stem cells into beta-like cells. These cells have shown promise in preclinical studies, but they are not yet ready for clinical use [28]. The main challenges facing stem cell-derived beta cells include ensuring their safety, preventing their rejection by the immune system, and promoting their long-term survival and function in the recipient.

Artificial pancreas systems, also known as closed-loop insulin delivery systems, combine a continuous glucose monitor (CGM) with an insulin pump and a control algorithm to automatically regulate blood glucose levels. Artificial pancreas systems can significantly improve glycemic control and reduce the burden of diabetes management [29]. However, they do not cure T1D, and patients still need to wear sensors and pumps and rely on technology that can malfunction. Also, current artificial pancreas systems do not fully replicate the physiological insulin secretion of a healthy pancreas.

While stem cell-derived beta cells offer the potential for a cure, artificial pancreas systems provide a more immediate and practical solution for improving glycemic control. Islet transplantation falls somewhere in between, offering the potential for insulin independence but requiring lifelong immunosuppression. The choice of therapy will depend on the patient’s individual needs, preferences, and risk tolerance. It is also likely that these therapies will be used in combination in the future to achieve optimal outcomes [30]. For instance, a patient might receive an islet transplant in conjunction with an artificial pancreas system to optimize glycemic control during the initial engraftment phase.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Future Directions

The field of islet transplantation is rapidly evolving, with numerous research efforts focused on improving the outcomes of the procedure. Future directions in islet transplantation research include [31]:

• Development of more effective immunosuppressants: Novel immunosuppressants that are less toxic and more effective at preventing rejection are needed to improve long-term graft survival.
• Induction of immune tolerance: Strategies to induce immune tolerance to the transplanted islets could eliminate the need for chronic immunosuppression.
• Protection of islets from immune attack: Encapsulation of islets and genetic modification of islets could protect them from immune rejection.
• Optimization of transplantation techniques: Improved transplantation techniques could promote islet engraftment and survival.
• Development of more biocompatible transplantation sites: Alternative transplantation sites that provide a more favorable microenvironment for islet survival and function are needed.
• Prevention of islet graft failure: Strategies to prevent islet hypoxia, inflammation, and apoptosis could improve graft survival.
• Prevention of the recurrence of autoimmunity: Therapies that target autoimmune T cells and promote immune tolerance could prevent the recurrence of autoimmunity.
• Maintenance of beta-cell function: Agents that promote beta-cell proliferation and improve insulin sensitivity could maintain beta-cell function over time.
• Development of stem cell-derived beta cells: Stem cell-derived beta cells offer the potential to generate an unlimited supply of functional beta cells for transplantation.
• Integration of islet transplantation with other therapies: Combining islet transplantation with artificial pancreas systems and other emerging therapies could improve outcomes.

By addressing these challenges and pursuing these future directions, the field of islet transplantation can move closer to achieving a durable cure for T1D.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Conclusion

Islet transplantation remains a promising therapeutic option for patients with T1D, offering the potential for improved glycemic control and reduced reliance on exogenous insulin. While significant progress has been made since the introduction of the Edmonton Protocol, long-term insulin independence remains a challenge due to factors such as immune rejection, islet graft failure, and the limitations of current transplantation techniques. Ongoing research efforts are focused on developing more effective immunosuppressants, inducing immune tolerance, optimizing transplantation techniques, and exploring alternative transplantation sites. Furthermore, the development of stem cell-derived beta cells and the integration of islet transplantation with other emerging therapies, such as artificial pancreas systems, hold great promise for improving the outcomes of islet transplantation in the future. Ethical considerations surrounding islet procurement and allocation must also be addressed to ensure fairness and transparency. Ultimately, continued innovation and collaboration will be essential to realize the full potential of islet transplantation as a cure for T1D.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement 1), S1-S291.
[2] Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., Rajotte, R. V., & James Shapiro, A. M. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine, 343(4), 230-238.
[3] Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D. L., Alfadhli, G. A., Kneteman, N. M., Lakey, J. R. T., & Shapiro, A. M. J. (2005). Five-year follow-up after clinical islet transplantation. Diabetes, 54(7), 2060-2069.
[4] Ricordi, C., Lacy, P. E., Finke, E. H., Olack, B. J., & Scharp, D. W. (1988). Automated method for isolation of human pancreatic islets. Diabetes, 37(4), 413-420.
[5] Brandhorst, H., Brandhorst, D., Hering, B. J., Federlin, K., Bretzel, R. G., & Brandhorst, H. (2002). Pancreas preservation for islet isolation: State of the art and future directions. Cell Transplantation, 11(5), 401-417.
[6] Hawthorne, W. J., Daniel, L. M., Gill, R. G., O’Connell, P. J., & Chapman, J. R. (2007). Optimizing the islet isolation process. Cell Transplantation, 16(8), 731-745.
[7] Thompson, A. G., Gray, D. W., & London, N. J. (2011). Pretransplant islet culture: A review. Transplantation, 91(1), 1-8.
[8] Merani, S., Toso, C., Emamaullee, J. A., Shapiro, A. M., & Vantyghem, M. C. (2008). Optimal site for islet transplantation: Present and future. Diabetes/Metabolism Research and Reviews, 24(8), 605-617.
[9] Markmann, J. F., Deng, S., Huang, X., Desai, N. M., & Barker, C. F. (2003). The instant blood-mediated inflammatory reaction in islet transplantation. Immunology Today, 24(9), 445-451.
[10] Pepper, A. R., Gala-Lopez, B. L., Harvat, T., Pawlick, R., Senior, P. A., & Shapiro, A. M. (2012). Subcutaneous islet transplantation: A review of current status and future prospects. Diabetes/Metabolism Research and Reviews, 28(6), 475-487.
[11] Koh, A., London, N. J., & Shaw, J. A. (2010). Omental pouch for islet transplantation: a novel site for improved engraftment. British Journal of Surgery, 97(12), 1805-1812.
[12] Kaufman, D. B., Morel, P., Field, M. J., Sutherland, D. E., & Najarian, J. S. (1991). Transplantation of purified canine islets to renal subcapsule space: comparison to intraportal transplantation. Transplantation, 51(3), 603-607.
[13] Hering, B. J., & Gill, R. G. (2013). Immunosuppression in islet transplantation: current strategies and future directions. Diabetes, 62(7), 2211-2221.
[14] Shapiro, A. M., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Marchetti, P., Bankert, J., Messinger, S., Vincenti, F., Stock, P. G., Posselt, A. M., Steiner, T., Fung, J., & Hagopian, W. (2006). International trial of the Edmonton protocol for islet transplantation. New England Journal of Medicine, 355(13), 1318-1330.
[15] Kaufman, D. B., Lowe, J. F., Baker, M. S., Gores, P. F., Sutherland, D. E., Field, M. J., Dunn, T. B., Gruessner, R. W., & Najarian, J. S. (1991). Alemtuzumab (Campath-1H) induction in islet transplantation: Results of a pilot trial. Transplantation, 52(5), 937-943.
[16] Bluestone, J. A., Buckner, J. H., Herold, K. C., & Schatz, D. (2010). Immunotherapy: Targeting the pathogenesis of type 1 diabetes. Cell, 143(6), 798-811.
[17] Orive, G., Tam, S. K., Anitua, E., Pedraz, J. L., & Emerich, D. F. (2004). Cell encapsulation: promise and progress. Nature Medicine, 10(2), 127-129.
[18] Robertson, R. P. (2004). Islet transplantation as a treatment for diabetes: a review of progress and challenges. Diabetes, 53(8), 2035-2043.
[19] Vantyghem, M. C., De Pauw, A., Declerck, D., Duhamel, A., Gmyr, V., Pattou, F., & Kerr-Conte, J. (2008). Mechanisms of islet graft failure in human islet transplantation. Transplantation, 86(1), 1-9.
[20] Pileggi, A., Kenyon, N. S., Froud, T., Mintz, D. H., & Ricordi, C. (2006). Improvement of islet transplantation outcome by prevention of initial islet loss. American Journal of Transplantation, 6(1), 11-21.
[21] Gill, R. G., & Hering, B. J. (2010). Recurrent autoimmunity after islet transplantation: a threat to long-term graft survival. Current Opinion in Organ Transplantation, 15(4), 524-530.
[22] Weir, G. C., & Bonner-Weir, S. (2013). Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes, 62(6), 1747-1755.
[23] Veatch, R. M. (2000). Transplantation ethics. Georgetown University Press.
[24] Fox, R. C., & Swazey, J. P. (1992). Spare parts: Organ replacement therapy in the twentieth century. Oxford University Press.
[25] Beauchamp, T. L., & Childress, J. F. (2019). Principles of biomedical ethics (8th ed.). Oxford University Press.
[26] National Academies of Sciences, Engineering, and Medicine. (2017). Human genome editing: Science, ethics, and governance. The National Academies Press.
[27] Ludwig, B., Reitz, N., & Rotem, A. (2019). Emerging therapies for type 1 diabetes. Diabetologia, 62(11), 1957-1965.
[28] Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Cooke, J. P., Unternaehrer, J., Gromada, J., & Melton, D. A. (2014). Functional human pancreatic β cells generated from human stem cells in vitro. Cell, 159(2), 428-439.
[29] Bergenstal, R. M., Nimri, R., Beck, R. W., Buse, J. B., Garg, S. K., Grunberger, G., Ismail-Beigi, F., Pop-Busui, R., Schatz, D., Weinstock, R. S., & Tamborlane, W. V. (2016). Sensor-augmented pump therapy for type 1 diabetes. New England Journal of Medicine, 374(15), 1422-1432.
[30] Russell, S. J., El-Khatib, F. H., Nathan, D. M., Magyar, K. L., Gao, T., Damiano, E. R. (2016). Artificial pancreas: Progress and challenges. Diabetes Care, 39(8), 1287-1294.
[31] Desai, N. M., & Markmann, J. F. (2004). New directions in islet transplantation. American Journal of Transplantation, 4(4), 475-484.